Tag: vote

FREEHOLD, N.J., June 27, 2025 (GLOBE NEWSWIRE) -- Channel Therapeutics Corporation, (“Channel” or the “Company”), (NYSE American: CHRO), an emerging leader in the development of non-opioid pain treatment therapeutics, today announced a 10-for-one reverse split (the “Reverse Stock Split”) of the Company’s common stock (the “Common Stock”). The Reverse Stock Split is intended to increase the market price per share of the Company’s Common Stock and help the Company satisfy the initial listing requirements of the NYSE American (the “NYSE American”) in connection with the anticipated closing of the previously announced merger of CHRO Merger Sub, Inc., a wholly owned subsidiary of the Company, with and into LNHC, Inc. and the related approximately $50 million in capital to be raised from a group of strategic investors led by Murchinson (together, the “Proposed Transactions”).

CALGARY, Alberta, June 26, 2025 (GLOBE NEWSWIRE) -- Wilmington Capital Management Inc. (TSX: WCM.A, WCM.B) (“Wilmington”) held its Annual Meeting of Shareholders on June 26, 2025 in Calgary, Alberta and all two nominees proposed for election to the board of directors by holders of Class A Shares and all three nominees proposed for election to the board of directors by the holders of Class B Shares were elected. Detailed results of the vote for the election of directors are set out below.

GREENWICH, Conn., June 26, 2025 (GLOBE NEWSWIRE) -- Aetherium Acquisition (the “SPAC” or the “Company”), a publicly-traded special purpose acquisition company, today announced that its Special Meeting (“Meeting”), previously scheduled at 8:30 a.m. Eastern Time on June 27, 2025, has been postponed to 8:30 a.m. Eastern Time on July 7, 2025, and the redemption right deadline has been postponed to 5:00 p.m. Eastern Time on July 2, 2025.

Transparency Notification from Shareholders

New York, June 25, 2025 (GLOBE NEWSWIRE) -- Eureka Acquisition Corp (the “Company”) (Nasdaq: EURK), a blank check company, today announced that in connection with its previously announced extraordinary general meeting in lieu of an annual general meeting of shareholders to be held on June 30, 2025, at 9:00 a.m., Eastern Time (the “Extraordinary General Meeting”), the Company has revised the contribution to its trust account and the terms and conditions in connection with the proposal to amend the Company’s current Charter (the “Charter Amendment Proposal”).

Ad hoc announcement pursuant to Art. 53 LR

Basel, June 25, 2025 – Novartis today announced that it has successfully completed its acquisition of Regulus Therapeutics Inc. (“Regulus”). With the completion of the acquisition, shares of common stock, par value $0.001 per share (the “Shares”), of Regulus, have ceased trading on the Nasdaq Stock Market LLC and Regulus is now an indirect wholly owned subsidiary of Novartis.